SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Blackburn Stan

(Last)

(First)

(Middle)

3545 JOHN HOPKINS COURT, SUITE 250

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/20/2018

3. Issuer Name and Ticker or Trading Symbol
aTYR PHARMA INC [ LIFE ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director		10% Owner
Officer (give title below)	X	Other (specify below)
		See Remarks

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	11,954	I	By the J. Stanhope and Karlene S. Blackburn Family Trust U.T.D. May 2001⁽¹⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽²⁾⁽³⁾	06/02/2021	Common Stock	129	$0.72	D
Stock Option (right to buy)	⁽²⁾⁽³⁾	09/13/2022	Common Stock	878	$0.88	D
Stock Option (right to buy)	⁽²⁾⁽³⁾	09/26/2023	Common Stock	2,514	$4.06	D
Stock Option (right to buy)	⁽²⁾⁽³⁾	03/05/2024	Common Stock	1,760	$4.06	D
Stock Option (right to buy)	⁽²⁾⁽⁴⁾	04/17/2025	Common Stock	3,143	$9.15	D
Stock Option (right to buy)	⁽²⁾⁽⁵⁾	05/06/2025	Common Stock	4,085	$14	D
Stock Option (right to buy)	⁽²⁾⁽⁶⁾	10/01/2025	Common Stock	9,500	$10.24	D
Stock Option (right to buy)	⁽²⁾⁽⁷⁾	01/27/2026	Common Stock	4,250	$6.14	D

Explanation of Responses:

1. The Reporting Person is a co-trustee of the J. Stanhope and Karlene S. Blackburn Family Trust U.T.D. May 9, 2001.

2. All options reported on this Form 3 were granted prior to February 2016 when the Reporting Person was a consultant, serving as the Company's Acting Chief Financial Officer. On March 20, 2018, the Reporting Person became the Company's Principal Financial and Accounting Officer.

3. This option was fully vested and exercisable at the reporting date.

4. The shares subject to this option vest in 48 equal monthly installments starting on May 17, 2015 and will be fully exercisable on April 17, 2019. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.

5. The shares subject to this option vest in 48 equal monthly installments starting on June 6, 2015 and will be fully exercisable on May 6, 2019. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.

6. The shares subject to this option vest in 48 equal monthly installments starting on November 1, 2015 and will be fully exercisable on October 1, 2019. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.

7. The shares subject to this option vest in 48 equal monthly installments starting on February 1, 2016 and will be fully exercisable on January 1, 2020. This option is subject to accelerated vesting upon termination without cause upon a change in control of the Issuer.

Remarks:

Principal Financial and Accounting Officer

	Nancy D. Krueger, Attorney-In-Fact	05/02/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.